Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer

NCT03444376 is registered in ClinicalTrials.gov with Genexine, Inc. as lead sponsor.

NCT NCT03444376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03444376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Lead sponsor
Genexine, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 19, 2018
Completion date
December 21, 2023
Enrollment
65 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer